ReCode Therapeutics

We are proud to announce that ReCode’s lead therapeutic candidate, RCT1100, has received U.S. FDA Orphan Disease Designation for the treatment of primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene. PCD is a rare genetic lung disorder that currently has no FDA-approved treatments, so receiving this designation is an important recognition for the PCD patient community. We want to thank the entire ReCode team for their continued persistence in unlocking the potential of precision mRNA and gene correction therapeutics. We also thank the PCD Foundation, all people living with PCD, and their families for providing the feedback and insights that shape our research and power our progress. Learn more about RCT1100 here: https://lnkd.in/gv647SZs

Find out where we’ll be in July — check our latest calendar here: https://lnkd.in/gsWyhr8V

This #FourthOfJuly, we celebrate the spirit of freedom and innovation that defines our great nation. At ReCode, we are inspired by the resilience and determination that have shaped America's history and continue to drive us forward in our mission to revolutionize genetic medicine. To all those who have contributed to the pursuit of liberty and progress, we salute you. Happy Independence Day! #IndependenceDay #Innovation #GeneticMedicine

Find out where we’ll be in July — check our latest calendar here: https://lnkd.in/gsWyhr8V

Let’s talk about the symptoms of cystic fibrosis (CF). CF is a progressive, life-threatening genetic disease that can lead to severe respiratory and digestive problems if untreated. Swipe left on the graphic for some key symptoms you should be aware of. Recognizing these symptoms early can lead to a timely diagnosis and better management of CF, significantly enhancing the quality of life for those affected. #CysticFibrosis #GeneticMedicine #CFAwareness

Let's hear more from Teri Keffer, Vice President, People Strategy & HR at ReCode! Here, Teri shares her insights on empowering individuality while supporting organizational values: "To build a strong culture of engagement, it is important to recognize our team. We do this in three different ways: 1) Highlighting a peer-nominated monthly culture champion, 2) Offering a spot bonus program for exceptional key contributions beyond the scope of job responsibilities, 3) Our real-time peer/manager recognition and awards program. Accumulated awards can be cashed in for gift cards or charitable donations. The effect of these recognition systems is profound. When we survey our employees, this is always a key strength." At ReCode, we power the next wave of possibilities in genetic medicines for cystic fibrosis, primary ciliary dyskinesia, and beyond. #Individuality #Teamwork #AboveAndBeyond

On Juneteenth, we reflect on how far we've come and how much work remains in addressing the systemic disparities that minority communities continue to face, including a lack of access to basic healthcare services and underrepresentation in clinical trials. In particular, this lack of representation leads to gaps in treatment efficacy and overall health outcomes. As we commemorate Juneteenth, we must acknowledge these disparities and commit to closing the gap, ensuring equal access to healthcare for all.

Let's talk about cystic fibrosis (CF) - a progressive genetic disease that, if left untreated, can cause persistent lung infections and respiratory failure. What else do you need to know? Swipe to learn more and pass this along. What's something you'd like to bring to light about CF? #CysticFibrosis #GeneticMedicine #mRNA

On this World Blood Donor Day, we thank the donors and encourage those considering donation to take action. According to the American Red Cross, every two seconds, someone in the U.S. needs blood or platelets. There is a constant and critical demand for these life-saving resources. Genetic disorders require continuous research and the resources to develop innovative treatments; blood donations are a key component of this process. Thank you to all donors for your generosity and commitment to improving the health and lives of countless individuals. Your donation helps us build a healthier future for everyone.

For the first time, researchers show that LNPs carrying gene editing tools can effectively correct a gene in lung stem cells! Here, our Chief Scientific Officer, David Lockhart, explains the significance of this study, which was published today in Science Magazine. Congratulations to Daniel Siegwart, his team at UT Southwestern Medical Center, and the ReCode Therapeutics researchers who made this landmark study possible!